30-day FRN

Federal Register / Vol. 84, No. 106 / Monday, June 3, 2019 / Notices

jbell on DSK3GLQ082PROD with NOTICES

that the draft reports should be available
on the website by June 5, 2019.
Additional information will be posted
when available or may be requested in
hardcopy from Susan Blaine by phone:
(703) 225–2471 or email: NTPMeetings@icf.com. Individuals are
encouraged to access the meeting web
page to stay abreast of current
information regarding the meeting.
Following the meeting, a report of the
peer-review will be prepared and made
available on the NTP website.
Background Information on NTP PeerReview Panels: NTP panels are
technical, scientific advisory bodies
established on an ‘‘as needed’’ basis to
provide independent scientific peerreview and advise NTP on agents of
public health concern, new/revised
toxicological test methods, or other
issues. These panels help ensure
transparent, unbiased, and scientifically
rigorous input to the program for its use
in making credible decisions about
human hazard, setting research and
testing priorities, and providing
information to regulatory agencies about
alternative methods for toxicity
screening. NTP welcomes nominations
of scientific experts for upcoming
panels. Scientists interested in serving
on an NTP panel should provide their
current curriculum vitae to Susan
Blaine by email: NTP-Meetings@icf.com.
The authority for NTP panels is
provided by 42 U.S.C. 217a; section 222
of the Public Health Service Act, as
amended. The panel is governed by the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), which
sets forth standards for the formation
and use of advisory committees.
This peer review is being conducted
by a panel in attendance at NIEHS. Peerreview of future draft reports will be
conducted in accordance with
Department of Health and Human
Services peer-review policies (https://
aspe.hhs.gov/hhs-information-qualitypeer-review) and Office of Management
and Budget’s Final Information Quality
Bulletin for Peer Review (70 FR 2664,
January 4, 2005).
Dated: May 21, 2019.
Brian R. Berridge,
Associate Director, National Toxicology
Program.
[FR Doc. 2019–11463 Filed 5–31–19; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

National Institutes of Health

Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meetings

Submission for OMB Review; 30-Day
Comment Request; Center for Cancer
Training (CCT) Application Form for
Electronic Individual Development
Plan (eIDP) (National Cancer Institute)

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; ZHD1 DSR–A (50).
Date: July 12, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda Downtown,
7335 Wisconsin Ave., Bethesda, MD 20814.
Contact Person: Rita Anand, Ph.D.,
Scientific Review Officer, Division of
Scientific Review, National Institute of Child
Health and Human Development, NIH, 6710B
Rockledge Drive, Bethesda, MD 20892, 301–
496–1487, anandr@mail.nih.gov.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; NIH Infant and
Toddler Toolbox.
Date: July 25, 2019.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6710 B
Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Sathasiva B. Kandasamy,
Ph.D. Scientific Review Officer, Division of
Scientific Review, National Institute of Child
Health and Human Development, 6710B
Rockledge Drive, Bethesda, MD 20892–9304,
(301) 435–6680, skandasa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: May 28, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–11438 Filed 5–31–19; 8:45 am]
BILLING CODE 4140–01–P

VerDate Sep<11>2014

16:26 May 31, 2019

Jkt 247001

25553

PO 00000

Frm 00036

Fmt 4703

Sfmt 4703

AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
ADDRESSES: Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, should be
directed to the: Office of Management
and Budget, Office of Regulatory Affairs,
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974, Attention: Desk
Officer for NIH.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Erika Ginsburg,
Scientific Program Analyst, Center for
Cancer Training, National Cancer
Institute, 9609 Medical Center Drive,
Room 2W–106, Bethesda, Maryland
20892 or call non-toll-free number (240)
276–5627 or Email your request,
including your address to: ginsbure@
mail.nih.gov. Formal requests for
additional plans and instruments must
be requested in writing.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register on March 15, 2019, page 9537
(Vol. No. 84 FR 9537 and allowed 60
days for public comment. No public
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment. The
National Cancer Institute (NCI),
National Institutes of Health, may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
SUMMARY:

E:\FR\FM\03JNN1.SGM

03JNN1

25554

Federal Register / Vol. 84, No. 106 / Monday, June 3, 2019 / Notices

In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: Center for
Cancer Training (CCT) Application
Form for electronic Individual
Development Plan (eIDP), 0925–XXXX,
Exp., Date XX/XXXX, NEW, National
Cancer Institute (NCI), National
Institutes of Health (NIH).
Need and Use of Information
Collection: The National Cancer
Institute’s (NCI) Center for Cancer
Training (CCT) supports NCI’s goal of
training cancer researchers with various

educational levels (postbaccalaureate,
graduate students, postdoctoral fellows)
and for varying periods of time (3
months to 5 years). The eIDP is an
online, detailed questionnaire focused
on responses to career and professional
goals and expectations while the trainee
works at the NCI. The eIDP ensures the
NCI trainees are receiving proper career
and professional guidance, making
appropriate progress, and determining
activities to achieve their goals. The
eIDP is also used to track trainees’
career and professional goals and to
ensure trainees receive the tools needed
to achieve those goals. It is expected the
trainees will complete the eIDP
annually and that the eIDP process
could be improved by their responses.
The effectiveness of training could also

be enhanced by the reports received by
the trainees completing the eIDP.
Individual Development Plans have
been collected by paper and pencil from
trainees since 2001. With the
implementation of the electronic
system, a pilot of the eIDP was approved
by OMB (#0925–0046) and implemented
in December 2018. The pilot improved
the clarity of the instructions for the
eIDP system, and incorporated feedback
from the trainees to improve the overall
trainee IDP experience, which advances
the effectiveness of training
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden are 1,209
hours.

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Type of respondent

Average time
per response
(in hours)

Total annual
burden hours

Individuals—Trainees ......................................................................................
Individuals—Alumni .........................................................................................
Individuals—Feedback .....................................................................................

1,000
500
500

1
1
1

1
5/60
20/60

1,000
42
167

Totals ........................................................................................................

1,000

1,000

........................

1,209

Patricia M. Busche,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
[FR Doc. 2019–11460 Filed 5–31–19; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice
AGENCY:

The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or

SUMMARY:

jbell on DSK3GLQ082PROD with NOTICES

Number of
responses per
respondent

VerDate Sep<11>2014

16:26 May 31, 2019

Jkt 247001

IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at http://www.samhsa.gov/
workplace.
FOR FURTHER INFORMATION CONTACT:

Charles LoDico, Division of Workplace
Programs, SAMHSA/CSAP, 5600
Fishers Lane, Room 16N02C, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITF) currently
certified to meet the standards of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory
Guidelines were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April

PO 00000

Frm 00037

Fmt 4703

Sfmt 4703

30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated January 23, 2017 (82
FR 7920), the following HHS-certified
laboratories and IITFs meet the
minimum standards to conduct drug

E:\FR\FM\03JNN1.SGM

03JNN1